<DOC>
	<DOCNO>NCT00231166</DOCNO>
	<brief_summary>The purpose study determine high tolerate dose , safety activity HCD122 patient Multiple Myeloma relapse receive prior treatment .</brief_summary>
	<brief_title>Safety , Efficacy , Dose-finding Study Monoclonal Antibody Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Clinical Diagnosis MM require treatment Refractory Relapsed Disease At least one prior treatment regimen Male Female &gt; 18 year age Prior Allogeneic bone marrow transplant ( prior autologous transplant allow ) Intracranial disease epidural disease Clinically significant cardiac dysfunction significant organ dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>dose-finding</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>